Clinical trials: Pembrolizumab
Non-small Cell Lung Cancer (NSCLC)
A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of tiragolumab in combination with atezolizumab plus pemetrexed and carboplatin/cisplatin (Arm A) compared with placebo in combination with…
- Trial name
- SKYSCRAPER-06 (NCT04619797)
- Testing
- Tiragolumab, Atezolizumab, Pemetrexed
- Where
- 127 sites in United States, Belgium and 19 more
- Volunteers
- 542 people
- Sponsor
- Hoffmann-La Roche
SCCHN
Combination Therapy With NC-6004 and Pembrolizumab in Head and Neck Cancer Subjects Who Have Failed Platinum Regimen
In Phase IIa, dose-escalation study to determine the optimum tolerated dose and a recommended Phase IIb (RPIIb) dose in combination with pembrolizumab in subjects with recurrent or metastatic squamous cell carcinoma of the head…
- Trial name
- NCT03771820
- Testing
- NC-6004, Pembrolizumab
- Where
- 24 sites in Croatia, Czechia and 6 more
- Volunteers
- 136 people
- Sponsor
- NanoCarrier Co., Ltd.
Melanoma
Radiation Therapy, Plasma Exchange, and Immunotherapy (Pembrolizumab or Nivolumab) for the Treatment of Melanoma
This early phase I trial investigates how well radiation therapy, plasma exchange, and pembrolizumab or nivolumab work in treating patients with melanoma.
- Trial name
- NCT04581382
- Testing
- Nivolumab, Pembrolizumab, Radiation Therapy
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Mayo Clinic
Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer
Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)
This is a Phase 3, multicenter, open-label, randomized study of nemvaleukin in combination with pembrolizumab versus protocol-specific Investigator's choice chemotherapy in patients with platinum-resistant epithelial ovarian…
- Conditions
- Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- ARTISTRY-7 (NCT05092360)
- Testing
- Nemvaleukin and Pembrolizumab Combination, Pembrolizumab, Nemvaleukin
- Where
- 117 sites in United States, Australia and 12 more
- Volunteers
- 456 people
- Sponsor
- Mural Oncology, Inc
Non-small Cell Lung Cancer (NSCLC)
Study of Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Platinum-based Doublet Chemotherapy as First-line Treatment for Participants With Locally Advanced or Metastatic NSCLC.
The primary scientific question of interest is whether the addition of ociperlimab to platinum-based chemotherapy and tislelizumab improve progression-free survival (PFS) or overall survival (OS) compared to pembrolizumab and…
- Trial name
- AdvanTIG-306 (NCT05791097)
- Testing
- Ociperlimab, Tislelizumab, Pembrolizumab
- Sponsor
- Novartis Pharmaceuticals
Pancreatic Cancer
Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas
The purpose of this study is to evaluate whether combining cyclophosphamide (CY), pembrolizumab, GVAX and IMC-CS4 is effective and safe in patients with borderline resectable pancreatic cancer.
- Trial name
- NCT03153410
- Testing
- Cyclophosphamide, GVAX Pancreas Vaccine (GVAX), Pembrolizumab
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Solid Tumor, Non Small Cell Lung Cancer
A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors
This is a phase I, First-in-Human (FIH), open-label study to evaluate the safety, tolerability, pharmacokinetic (PK) profile, and preliminary efficacy of AB248 as monotherapy OR in combination with pembrolizumab in adult…
- Conditions
- Solid Tumor, Non Small Cell Lung Cancer, Melanoma, Squamous Cell Carcinoma of Head and Neck
- Trial name
- NCT05653882
- Testing
- etakafusp alfa (AB248), pembrolizumab
- Where
- 20 sites in United States
- Volunteers
- 552 people
- Sponsor
- Asher Biotherapeutics, Inc.
Leukemia, B-cell, Lymphoma, B-Cell
Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma
This study combines the immune checkpoint inhibitor pembrolizumab with the BITE antibody blinatumomab for the treatment of relapsed/refractory pre-B cell ALL.
- Trial name
- NCT03605589
- Testing
- Blinatumomab, Pembrolizumab
- Where
- United States
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Non-small Cell Lung Cancer, Bladder Cancer
CVA21 and Pembrolizumab in NSCLC & Bladder Cancer (VLA-009 STORM/ KEYNOTE-200)
The purpose of this trial is to assess the ability of CVA21, either alone (Part A) or in combination with pembrolizumab (Part B), to reach and to replicate in existing tumors (while sparing normal cells) and to establish a safe…
- Trial name
- STORM (NCT02043665)
- Testing
- CVA21/pembrolizumab
- Where
- 18 sites in United States, Australia and 1 more
- Volunteers
- 85 people
- Sponsor
- Viralytics
Endometrial Cancer
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
DESTINY-Endometrial01 will investigate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and/or T-DXd+ pembrolizumab (Arm B) when compared to chemotherapy (carboplatin + paclitaxel) + pembrolizumab (Arm C), by assessment…
- Trial name
- DE-01 (NCT06989112)
- Testing
- Trastuzumab deruxtecan, Rilvegostomig, Pembrolizumab
- Where
- 257 sites in United States, Australia and 21 more
- Volunteers
- 600 people
- Sponsor
- AstraZeneca
Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)
The purpose of this study is to compare eftilagimod alfa (efti) in combination with pembrolizumab and chemotherapy versus placebo in combination with pembrolizumab and chemotherapy with respect to overall survival (OS) and…
- Trial name
- NCT06726265
- Testing
- eftilagimod alfa, carboplatin plus paclitaxel, cisplatin or carboplatin + pemetrexed
- Where
- 147 sites in United States, Argentina and 25 more
- Volunteers
- 756 people
- Sponsor
- Immutep S.A.S.
Advanced or Metastatic Solid Tumors, Breast Cancer
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
The purpose of this study is to characterize the safety, tolerability, and efficacy of IDE161 as a single agent and in combination with pembrolizumab.
- Conditions
- Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Prostate Cancer
- Trial name
- NCT05787587
- Testing
- IDE-161, Pembrolizumab
- Where
- 27 sites in United States
- Volunteers
- 216 people
- Sponsor
- IDEAYA Biosciences
Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Adenocarcinoma
Pembrolizumab and CXCR4 Antagonist BL-8040 in Treating Patients With Metastatic Pancreatic Cancer
This pilot phase IIb trial studies how well pembrolizumab and CXCR4 antagonist BL-8040 work in treating patients with pancreatic cancer that has spread to other places.
- Conditions
- Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v6 and v7
- Trial name
- NCT02907099
- Testing
- CXCR4 Antagonist BL-8040, Pembrolizumab, Pharmacological Study
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Solid Tumors
Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001)
This study will assess the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of escalating doses of quavonlimab when used in combination with pembrolizumab in participants with advanced solid tumors.
- Trial name
- NCT03179436
- Testing
- Quavonlimab, Pembrolizumab, Pembrolizumab/Quavonlimab
- Where
- 53 sites in United States, Australia and 14 more
- Volunteers
- 415 people
- Sponsor
- Merck Sharp & Dohme LLC
Ovarian Squamous Cell Carcinoma
Assessment of the Efficacy and Safety of Pembrolizumab for Ovarian Squamous Cell Carcinoma
This is a phase II, non-randomized, open-label, single-arm, multicenter study to evaluate the efficacy and safety of MK-3475 in patients with ovarian squamous cell carcinoma.
- Trial name
- NCT05737199
- Testing
- MK-3475 (pembrolizumab)
- Where
- Japan
- Volunteers
- 21 people
- Sponsor
- Niigata University Medical & Dental Hospital
Glioblastoma
Evaluation Of The Treatment Effectiveness Of Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475
It is known that after application of MK-3475 activated PD -1 negatively regulates the activation of T cells through suppression of the path of PI3K / Akt.
- Trial name
- NCT02430363
- Testing
- MK - 3475, Suppressor of the PI3K/Akt pathways
- Where
- 13 sites in United States, Belgium and 8 more
- Volunteers
- 58 people
- Sponsor
- Medical Research Council
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061/KEYNOTE-061)
This is a study for participants with advanced gastric or gastroesophageal junction adenocarcinoma who have had tumor progression after first-line treatment with platinum and fluoropyrimidine doublet therapy.
- Trial name
- NCT02370498
- Testing
- pembrolizumab, paclitaxel
- Volunteers
- 592 people
- Sponsor
- Merck Sharp & Dohme LLC
Recurrent Platinum-Resistant Fallopian Tube Carcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma
P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
This phase II trial studies how well modified vaccinia virus ankara vaccine expressing p53 (p53MVA) and pembrolizumab work in treating patients with ovarian, primary peritoneal, or fallopian tube cancer that has come back…
- Conditions
- Recurrent Platinum-Resistant Fallopian Tube Carcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma, Recurrent Platinum-Resistant Primary Peritoneal Carcinoma
- Trial name
- NCT03113487
- Testing
- Modified Vaccinia Virus Ankara Vaccine Expressing p53, Pembrolizumab
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- City of Hope Medical Center
ccRCC
Pembrolizumab Plus Lenvatinib in REcurrent ccRCC Patients Failing permbroLizUmab aDjuvant trEatment
This study is being performed as a single-arm open-label study in order to provide information on the potential benefits of the combination of pembrolizumab and lenvatinib in participants with advanced ccRCC who have progressed…
- Trial name
- PRELUDE (NCT07460206)
- Testing
- Pembrolizumab 200 mg Q3W, Lenvatinib 20mg QD
- Volunteers
- 108 people
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
Brain Cancer, Brain Neoplasm
Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects
Glioblastoma (GBM) and gliosarcoma (GS) are the most common and aggressive forms of malignant brain tumor in adults and can be resistant to conventional therapies.
- Conditions
- Brain Cancer, Brain Neoplasm, Glioma, Glioblastoma
- Trial name
- CAPTIVE (NCT02798406)
- Testing
- DNX-2401, pembrolizumab
- Where
- 15 sites in United States, Canada
- Volunteers
- 49 people
- Sponsor
- DNAtrix, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.